Johnson & Johnson (NYSE:JNJ) Shares Sold by 1834 Investment Advisors Co.

1834 Investment Advisors Co. cut its position in Johnson & Johnson (NYSE:JNJ) by 8.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,197 shares of the company’s stock after selling 4,534 shares during the period. 1834 Investment Advisors Co.’s holdings in Johnson & Johnson were worth $7,811,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Wisconsin Capital Management LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at about $203,000. Catalina Capital Group LLC increased its holdings in shares of Johnson & Johnson by 22.2% in the third quarter. Catalina Capital Group LLC now owns 8,098 shares of the company’s stock valued at $1,312,000 after purchasing an additional 1,473 shares during the period. Avidian Wealth Enterprises LLC grew its holdings in Johnson & Johnson by 2.8% during the third quarter. Avidian Wealth Enterprises LLC now owns 16,749 shares of the company’s stock worth $2,714,000 after acquiring an additional 452 shares during the period. Beacon Financial Advisory LLC grew its holdings in Johnson & Johnson by 1.4% during the third quarter. Beacon Financial Advisory LLC now owns 8,438 shares of the company’s stock worth $1,367,000 after acquiring an additional 116 shares during the period. Finally, Balentine LLC grew its holdings in Johnson & Johnson by 76.0% during the third quarter. Balentine LLC now owns 7,748 shares of the company’s stock worth $1,256,000 after acquiring an additional 3,345 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $157.76 on Thursday. The company has a market cap of $379.83 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53. The stock’s 50 day simple moving average is $162.96 and its 200-day simple moving average is $155.76. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the business posted $2.66 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.14%. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Citigroup raised their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.